Jong Sun Park1, Ji Sun Lee2, Min Young Kim2, Chang Hoon Lee3, Ho Il Yoon1, Sang-Min Lee2, Chul-Gyu Yoo2, Young Whan Kim2, Sung Koo Han2, Jae-Joon Yim4. 1. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul, South Korea. 2. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine, Seoul, South Korea. 3. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, South Korea. 4. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine, Seoul, South Korea. Electronic address: yimjj@snu.ac.kr.
Abstract
BACKGROUND: Interferon-γ (IFN-γ) release assays (IGRAs), which can overcome several limitations of the tuberculin skin test in detecting latent TB infection, were introduced recently in routine clinical practice. However, IGRAs are highly dynamic tests, and the T-cell responses tend to fluctuate over time. We wanted to evaluate the conversion and reversion rates of monthly IGRAs over 1 year among health-care workers (HCWs) in contact with patients with TB in South Korea, a country with an intermediate TB burden. METHODS: Forty-nine HCWs in contact with patients with active pulmonary TB were prospectively enrolled. Interviews on exposure to patients with active TB, a physical examination, and a QuantiFERON TB Gold In-Tube assay (QFT-GIT) were carried out monthly for 1 year. RESULTS: Among 48 participants, 25 (52%) showed inconsistent results in serial testing. When an increase from< 0.35 IU/mL to ≥ 0.70 IU/mL was applied as the definition of a conversion, inconsistent IGRA results were identified in 13 participants (27.0%). Consistency in QFT-GIT results was associated with age, length of service, and baseline IFN-γ levels, but not with the profession of the participant, degree of TB exposure, or wearing of an N95 mask. In five participants, fluctuations in IFN-γ levels showed levels > 0.70 IU/mL two or more times. CONCLUSIONS: Fluctuation in IGRA findings was common when HCWs in contact with patients with TB were tested monthly. This could be a result of poor reproducibility of the assay, repeated infection and true reversion, or periodic secretion of antigens from Mycobacterium tuberculosis. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01121068; URL: www.clinicaltrials.gov
BACKGROUND: Interferon-γ (IFN-γ) release assays (IGRAs), which can overcome several limitations of the tuberculin skin test in detecting latent TBinfection, were introduced recently in routine clinical practice. However, IGRAs are highly dynamic tests, and the T-cell responses tend to fluctuate over time. We wanted to evaluate the conversion and reversion rates of monthly IGRAs over 1 year among health-care workers (HCWs) in contact with patients with TB in South Korea, a country with an intermediate TB burden. METHODS: Forty-nine HCWs in contact with patients with active pulmonary TB were prospectively enrolled. Interviews on exposure to patients with active TB, a physical examination, and a QuantiFERON TB Gold In-Tube assay (QFT-GIT) were carried out monthly for 1 year. RESULTS: Among 48 participants, 25 (52%) showed inconsistent results in serial testing. When an increase from< 0.35 IU/mL to ≥ 0.70 IU/mL was applied as the definition of a conversion, inconsistent IGRA results were identified in 13 participants (27.0%). Consistency in QFT-GIT results was associated with age, length of service, and baseline IFN-γ levels, but not with the profession of the participant, degree of TB exposure, or wearing of an N95 mask. In five participants, fluctuations in IFN-γ levels showed levels > 0.70 IU/mL two or more times. CONCLUSIONS: Fluctuation in IGRA findings was common when HCWs in contact with patients with TB were tested monthly. This could be a result of poor reproducibility of the assay, repeated infection and true reversion, or periodic secretion of antigens from Mycobacterium tuberculosis. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01121068; URL: www.clinicaltrials.gov
Authors: Madhukar Pai; Claudia M Denkinger; Sandra V Kik; Molebogeng X Rangaka; Alice Zwerling; Olivia Oxlade; John Z Metcalfe; Adithya Cattamanchi; David W Dowdy; Keertan Dheda; Niaz Banaei Journal: Clin Microbiol Rev Date: 2014-01 Impact factor: 26.132
Authors: John L Johnson; Hendrik Geldenhuys; Bonnie A Thiel; Asma Toefy; Sara Suliman; Bernadette Pienaar; Phalkun Chheng; Thomas Scriba; W Henry Boom; Willem Hanekom; Mark Hatherill Journal: Chest Date: 2014-03-01 Impact factor: 9.410
Authors: Song Yee Kim; Moo Suk Park; Young Sam Kim; Se Kyu Kim; Joon Chang; Dongeun Yong; Hyun Sook Kim; Kyungwon Lee; Young Ae Kang Journal: PLoS One Date: 2013-05-24 Impact factor: 3.240
Authors: Alice Zwerling; Andrea Benedetti; Mihaela Cojocariu; Fiona McIntosh; Filomena Pietrangelo; Marcel A Behr; Kevin Schwartzman; Dick Menzies; Madhukar Pai Journal: PLoS One Date: 2013-01-31 Impact factor: 3.240